CAS: 98708-80-6; 2-Amino-3-(4-(Tert-Butyl)Phenyl)Propanoic Acid

该化合物是一种非天然氨基酸衍生物,具有异丁基替代苯基组,具有增强其消毒和电子特性的亚丁基替代苯组,该化合物在合成和药用化学中特别宝贵,其中大丁基丙基组可影响相容稳定性和受体结合的相互作用.其结构特性使得它有助于设计酶抑制剂,生物活性药剂和其他药用相关分子.三丁基基分子还改善了脂性,有可能提高药物开发应用中的膜渗透性.这种氨基酸衍生物通常被用作有机和生物合成化学的建筑块,为研究人员提供定制分子特性的灵活工具.

结构式图片

上下游产品

CAS号871326-80-6 4-tert-butyl-N-... | CAS号871326-79-3 (4-tert-butyl-b... | CAS号871326-78-2 (4-tert-butyl-b... | CAS号19692-45-6 4-叔丁基苄氯 | CAS号282524-82-7 3-氨基-3-(4-叔丁基苯基)丙酸

合成工艺路线路线简述

    📜对叔丁基氯苄置于sodium Hydroxide,Potassium Carbonate,苯胺,Potassium Iodide体系中,用 乙醇,水,丙酮,Petroleum Ether 作为反应溶剂,化学反应 27.0H,反应生成 Dl-4-叔丁基苯丙氨酸
    参考文献:电化学放射性氟化.3. 阳极氧化后用 [18F] 氟化物直接标记苯丙氨酸衍生物
    标题:电化学放射性氟化.3. 阳极氧化后用 [18F] 氟化物直接标记苯丙氨酸衍生物
    摘要:作为在放射性氟化中应用电化学方法的一个例子,开发了一种通过直接使用 [18F] 氟化物制备 [18F] 氟苯丙氨酸的新程序.研究了苯丙氨酸的氨基和羧基功能的几个保护基团.n-三氟乙酰苯丙氨酸甲酯 (1) (10.5+/-2.5%) 获得了最佳结果,其相对异构体分布为 50.5+/-1.5% 的邻位异构体,11.5+/-1.5% 的间位异构体和 38.8+/-2.1% 的对位异构体.优化的反应条件是使用 Et3N.3Hf 作为支持电解质,温度在 0 到-10oc 之间.通过工作电位 (1.5-2.0 V) 和氯化物浓度(作为支持电解质添加,0.0-0. 36 M) 证明间接电解作为反应机制或卤素交换 (Halex) 反应,主要形成氯化产物,然后进行卤素交换是极不可能的.版权所有 © 2005 John Wiley & Sons,Ltd.
    DOI:10.1002/jlcr.918

    海关参考信息

    专利信息


    专利号:US-7763734-B2
    优先权日:2006-04-19
    标题 :Synthesis, structure and use of bisoxazolidines for asymmetric catalysis and synthesis
    发明人:WOLF CHRISTIAN; LIU SHUANGLONG
    权利人:UNIV GEORGETOWN
    摘要:One aspect of the invention relates to chiral bisoxazolidines and their use in asymmetric catalysis. The chiral bisoxazolidines are a novel class of compounds that is expected to find multiple applications, for example, in asymmetric synthesis. For example, a bisoxazolidine ligand enabled the catalytic enantioselective alkynylation and alkylation of a range of aromatic and aliphatic aldehydes, generating chiral propargylic alcohols and secondary alcohols in high yields and enantiomeric excess.

    专利号:US-10407468-B2
    优先权日:2016-03-23
    标 题 :Methods for synthesizing α4β7 peptide antagonists
    发明人:BHANDARI ASHOK; MANTHATI SURESH KUMAR; MEHROTRA MUKUND M; ANANDAN SAMPATH-KUMAR; PATEL DINESH V
    权利人:PROTAGONIST THERAPEUTICS INC
    摘要:The present invention provides methods of making α4β7 peptide monomer and dimer antagonists. Methods of the present invention include solid phase and solution phase methods, as well as synthesis via condensation of smaller peptide fragments. Methods of the present invention further include methods directed to the synthesis of peptides comprising one or more penicillamine residues.

    专利号:US-2025289851-A1
    优先权日:2022-04-22
    标 题:Cyclic peptides for delivering therapeutics
    发明人:DOUGHERTY PATRICK; TOTARO KYLE A; DOMBROSKI AMANDA; GIESLER RILEY; ZHOU MING; STREETER MATTHEW; GOFFIN ALEC; QIAN ZIQING
    权利人:ENTRADA THERAPEUTICS INC
    摘要:The present disclosure relates to the synthesis of cyclic peptides that are able to effectively deliver cargo, e.g., a therapeutic moiety (TM), inside a cell to treat a variety of conditions and diseases.

    专利号:US-2022185846-A1
    优先权日:2019-03-28
    标 题:Methods for synthesizing beta-homoamino acids
    发明人:MANTHATI SURESH KUMAR; BHANDARI ASHOK; MASJEDIZADEH MOHAMMAD REZA
    权利人:PROTAGONIST THERAPEUTICS INC
    摘要:Methods of making β-homoamino acids as intermediate for synthesis of peptide monmer and dimer α4β7-antagonists are disclosed. The disclosed methods include solid phase and solution phase methods.

    专利号:US-2007265255-A1
    优先权日:2006-04-19
    标题 :Synthesis, structure and use of bisoxazolidines for asymmetric catalysis and synthesis

    专利号:US-2009197800-A1
    优先权日:2004-10-27
    标 题:Insulin Receptor Binding Peptides with Non-Insulin Gene Activation Profiles and Uses Thereof
    发明人:SCHAFFER LAUGE; FREDERIKSEN KLAUS STENSGAARD
    权利人:NOVO NORDISK AS
    摘要:Methods for binding insulin receptors (and typically activating one or more function of an insulin receptor) by contacting insulin receptor-presenting cells, such as cells in a subject, with an effective amount of one or more insulin receptor binding peptides, where upregulation of one or more components of the insulin receptor-associated cholesterol synthesis pathway is not desired, are provided.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献

    合成方法参考DOI号:10.1002/jlcr.918
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知